General MedicationsORALGeneric

CAFCIT

CAFFEINE CITRATE

Standard Dose

EQ 30MG BASE/3ML (EQ 10MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview CAFCIT is listed in Drugs@FDA under application 020793 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient CAFFEINE CITRATE Form and strength SOLUTION;ORAL - EQ 30MG BASE/3ML (EQ 10MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor HIKMA Submission history Latest submission status date: 2020-03-02 00:00:00.

Structured Monograph

Clinical summary

Approval overview CAFCIT is listed in Drugs@FDA under application 020793 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CAFFEINE CITRATE Form and strength SOLUTION;ORAL - EQ 30MG BASE/3ML (EQ 10MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor HIKMA Submission history Latest submission status date: 2020-03-02 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.